News

Early FDA data with a femtosecond laser platform (VisuMax, Carl Zeiss Meditec) show positive results for corneal refractive surgery to treat uncomplicated myopia.

Initial FDA clinical trial outcomes of a femtosecond laser system (VisuMax, Carl Zeiss Meditec) to correct spherical myopia showed solid clinical and safety results.

Results from long-term follow-up support the use of a bifocal corneal inlay (Flexivue Microlens, Presbia) for presbyopia correction in emmetropic patients.

Outcomes for a cohort of patients with presbyopia with a small-aperture corneal inlay implanted find the device is well tolerated and patient satisfaction is high.

A new femtosecond laser system (Victus, Bausch + Lomb) is a reliable tool for creating high-quality LASIK flaps of intended dimensions.

An aspheric hydrogel corneal inlay (Raindrop Near Vision Inlay, ReVision Optics) appears very promising for presbyopia in emmetropic patients.

A femtosecond laser platform (IntraLase 150 kHz, Abbott Medical Optics) creates low-energy incisions that are safe, effective, accurate and reproducible for treating astigmatism associated with penetrating keratoplasty.

Cultural competency in medical care matters because it improves outcomes, is imperative because of demographic shifts, and is the law.

Postoperative hypotony is a problem not often seen by ophthalmologists, but when it occurs, elucidating its exact cause and treating it properly is imperative.

In a comparison study of elliptical and round femtosecond laser flaps created during myopic LASIK, both flap configurations provided excellent early results and patient satisfaction was very high.

Once again, Einstein’s theory of relativity gives rise

Be careful of what you ask; it may soon come true, relates columnist

Recurrent retinal detachments in children can develop months to years after the initial corrective surgery, making careful monitoring of patients imperative to identifying late re-detachments.

STAAR Surgical Co. has received regulatory approvals to market its Visian Implantable Collamer Lens (ICL) with CentraFLOW technology from the KFDA in Korea and the ANMAT in Argentina.

Prevent Blindness America (PBA) officially has launched its “3rd Annual Most Beautiful Eyes Contest.” The contest allows children across the United States the chance to win a $10,000 educational scholarship.

The Macula Vision Research Foundation (MVRF) has announced its 2013-2014 grant recipients.

iCo Therapeutics Inc. announced it has completed enrollment of its phase II iDEAL Study, which will evaluate the efficacy and safety after repeated injections of iCo-007 in patients with diabetic macular edema (DME).

Extensive studies in animals and initial experience in human trials support interest in integrin peptide therapy as an emerging new class of treatment for vascular eye disease, according to Baruch Kuppermann, MD, PhD.

Nicox S.A. has entered into an exclusive agreement with Immco Diagnostics Inc., which manufactures autoimmune diagnostic products and services, to promote a proprietary laboratory test targeted at early detection and diagnosis of Sjögren’s syndrome.

Sigma-Tau Pharmaceuticals Inc. has launched cysteamine ophthalmic solution 0.44% (Cystaran), the first and only FDA-approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

Perrigo Co. has acquired the ophthalmic portfolio of Fera Pharmaceuticals, a Long Island, NY-based specialty pharmaceutical company, for an upfront payment of $93 million.

The immediate postoperative period after PRK and LASIK can be difficult for patients because of refractive variations, surface irregularities, and poor optical clarity. However, a novel eye shield (Nexis Vision Corneal Shield, Nexis Vision) appears to help patients who have undergone PRK and LASIK by providing rapid visual and functional recovery.

Many Americans more than 50 years are not consuming enough specific nutrients in their daily diet to support their eye health. This was the conclusion from a recent review published in the Journal of Clinical Interventions in Aging.

The association of aspirin use and age-related macular degeneration (AMD) is controversial, considering the varying study results. The totality of evidence, however, from observational studies and randomized, controlled clinical trials suggests there is no major harmful association of aspirin use with AMD, said Emily Y. Chew, MD.

Vision-related diseases are costing patients, insurance companies, and the U.S. government more than ever. According to the new report commissioned by Prevent Blindness America (PBA) from researchers at the University of Chicago, vision diseases are among the costliest health problems to the U.S. economy.

The Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued a positive Appraisal Consultation Document (ACD) for the 190 µm fluocinolone acetonide intravitreal implant in applicator (Iluvien, Alimera Sciences) for the treatment of pseudophakic patients with chronic diabetic macular edema (DME) and who are unresponsive to existing therapies.

Using the strengths of both peristaltic and venturi phaco, a modified chop technique increases efficiency and safety in denser nuclei.

A new non-flared Kelman bent tip for torsional ultrasound phacoemulsification retains the same high-cutting efficiency of the mini-flared Kelman tip but without the latter’s propensity for inadvertent prolonged occlusion.

Outcomes from use of a proprietary femtosecond laser system (Catalys Precision Laser System, OptiMedica) to perform cataract surgery in a series of 850 eyes, of which 25% have some comorbidity, are testament to its reliability and safety.

Red Herring, a global media company that covers high-technology innovation, has chosen WaveTec Vision to receive the “Red Herring Top 100 North America Tech Startup” award.